Circulating endocannabinoids and affect regulation in human subjects

被引：24
作者：
Coccaro, Emil F. [1 ]
Hill, Matthew N. [2 ,3 ]
Robinson, Lauren [1 ]
Lee, Royce J. [1 ]
机构：
[1] Univ Chicago, Pritzker Sch Med, Dept Psychiat & Behav Neurosci, Clin Neurosci Res Unit, Chicago, IL 60637 USA
[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[3] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada
来源：
PSYCHONEUROENDOCRINOLOGY | 2018年 / 92卷
基金：
加拿大健康研究院;
关键词：
Endocannabinoids; Depression; Anxiety; Affect regulation; POSTTRAUMATIC-STRESS-DISORDER; CANNABINOID MODULATION; RECEPTOR AVAILABILITY; CEREBROSPINAL-FLUID; SYSTEM; ANANDAMIDE; REDUCTIONS; INHIBITION; ACTIVATION; VALIDITY;
D O I：
10.1016/j.psyneuen.2018.03.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The endocannabinoid (EC) system influences a wide variety of neurobiological processes including affect and emotionality as well as other neuropsychiatric functions. In this study we examined the relationship of circulating endocannabinoids [anandamide (AEA) and 2-arachidonoylglycerol (2-AG)] with affect and emotionality in 175 individuals with (n = 115) and without (n = 60) mood, anxiety, and/or personality disorders. Circulating AEA levels displayed a modest, though statistically significant, inverse relationship with a composite measure of affect regulation (beta = - 0.264, p = 0.009), due to its relationship with affect intensity (beta = - 0.225, p = 0.021) across all study participants. Neither AEA nor 2-AG level differed as a function of any syndromal/personality disorder and neither correlated significantly with state depression or state anxiety scores. These data suggest that circulating levels endocannabinoids may play a role in emotionality across individuals regardless of defined psychiatric disorder.
引用
收藏
页码：66 / 71
页数：6
相关论文
共 45 条
[11]   Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [J].
Christensen, Robin ;
Kristensen, Pernelle Kruse ;
Bartels, Else Marie ;
Blidda, Henning ;
Astrup, Arne .
LANCET, 2007, 370 (9600) :1706-1713
[12]   Personality disorder-not otherwise specified evidence of validity and consideration for DSM-5 [J].
Coccaro, Emil F. ;
Nayyer, Habiba ;
McCloskey, Michael S. .
COMPREHENSIVE PSYCHIATRY, 2012, 53 (07) :907-914
[13]   Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial [J].
Cooper, Ruth E. ;
Williams, Emma ;
Seegobin, Seth ;
Tye, Charlotte ;
Kuntsi, Jonna ;
Asherson, Philip .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (08) :795-808
[14]   Acute Stress Increases Circulating Anandamide and Other N-Acylethanolamines in Healthy Humans [J].
Dlugos, Andrea ;
Childs, Emma ;
Stuhr, Kara L. ;
Hillard, Cecilia J. ;
de Wit, Harriet .
NEUROPSYCHOPHARMACOLOGY, 2012, 37 (11) :2416-2427
[15]  
First M. B., 2001, STRUCTURED CLIN INTE
[16]   Individual differences in frontolimbic circuitry and anxiety emerge with adolescent changes in endocannabinoid signaling across species [J].
Gee, Dylan G. ;
Fetcho, Robert N. ;
Jing, Deqiang ;
Li, Anfei ;
Glatt, Charles E. ;
Drysdale, Andrew T. ;
Cohen, Alexandra O. ;
Dellarco, Danielle V. ;
Yang, Rui R. ;
Dale, Anders M. ;
Jernigan, Terry L. ;
Lee, Francis S. ;
Casey, B. J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (16) :4500-4505
[17]   Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain [J].
Glaser, ST ;
Gatley, SJ ;
Gifford, AN .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (03) :1088-1097
[18]   Divergent Effects of Genetic Variation in Endocannabinoid Signaling on Human Threat- and Reward-Related Brain Function [J].
Hariri, Ahmad R. ;
Gorka, Adam ;
Hyde, Luke W. ;
Kimak, Mark ;
Halder, Indrani ;
Ducci, Francesca ;
Ferrell, Robert E. ;
Goldman, David ;
Manuck, Stephen B. .
BIOLOGICAL PSYCHIATRY, 2009, 66 (01) :9-16
[19]  
HARVEY PD, 1989, J CLIN PSYCHOL, V45, P786, DOI 10.1002/1097-4679(198909)45:5<786::AID-JCLP2270450515>3.0.CO
[20]  
2-P
12345